Why Britain’s regeneration policies keep missing the point – expert panel

After the mainstream parties suffered big losses in Britain’s local elections in May, they might be wondering how they can win back voters in left-behind parts of the country. Labour’s Pride in Place scheme – £5.8 billion to be shared between some of the UK’s most deprived communities – doesn’t seem to have won the […]

How Maison Schiaparelli pioneered a new form of fashion currency

In a luxury market often blamed for flattening creativity, Maison Schiaparelli has long stood out for its defiant unconventionality. Where Coco Chanel’s creations exalted the functional elegance of the modern woman, Elsa Schiaparelli was interpreting her dreams, transforming her dresses into intellectual statements. The story of how Elsa Schiaparelli did this is celebrated in Schiaparelli: […]

The hidden history of Wales and the Jewish world

Jewish history in Wales stretches back centuries, yet its significance remains little known outside specialist circles. My new book uncovers how Jews, Judaism, Israel and Palestine have played a far greater role in Welsh history and imagination than many realise. In fact, they have helped shape ideas of nationhood, identity and belonging over centuries. In […]

Boys want to challenge harmful ideas about manhood – working with them, not lecturing them, is the key

BearFotos/Shutterstock In a recent BBC documentary, former England men’s football manager Gareth Southgate explored the challenges facing young men in Britain, including low school attainment, declining employment opportunities, low self-esteem and poor mental health. The positive masculinity Southgate promotes focuses on ambition to achieve, emotional openness, resilience and learning from setbacks, advocating for the role […]

Ovarian cancer drug approved for NHS use will prolong lives

More than 7,500 women are diagnosed with ovarian cancer every year. LADYMAYPIX/ Shutterstock A drug that can treat chemotherapy-resistant ovarian cancer has just been approved for use on the NHS in England. Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years. In […]